Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.420
-0.080 (-5.33%)
May 14, 2025, 10:14 AM - Market open
Editas Medicine Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 138.69 | 131.54 | 123.65 | 141.52 | 203.52 | 139.68 | Upgrade
|
Short-Term Investments | 82.27 | 138.37 | 199.46 | 202.75 | 296.33 | 262.43 | Upgrade
|
Cash & Short-Term Investments | 220.96 | 269.91 | 323.11 | 344.27 | 499.85 | 402.11 | Upgrade
|
Cash Growth | -25.39% | -16.46% | -6.15% | -31.12% | 24.31% | -12.04% | Upgrade
|
Accounts Receivable | 0.51 | 16.27 | 10.19 | 5.15 | 0.27 | 6.05 | Upgrade
|
Receivables | 0.51 | 16.27 | 10.19 | 5.15 | 0.27 | 6.05 | Upgrade
|
Prepaid Expenses | 3.37 | 3.14 | 7.53 | 7.34 | 7.2 | 10.93 | Upgrade
|
Total Current Assets | 224.84 | 289.32 | 340.83 | 356.75 | 507.31 | 419.09 | Upgrade
|
Property, Plant & Equipment | 34.61 | 47.05 | 45.71 | 59.22 | 43.29 | 39.15 | Upgrade
|
Long-Term Investments | - | - | 104.02 | 93.1 | 120.07 | 109.66 | Upgrade
|
Other Long-Term Assets | 4.2 | 5.22 | 8.59 | 5.25 | 6.81 | 4.7 | Upgrade
|
Total Assets | 263.65 | 341.59 | 499.15 | 514.32 | 677.48 | 572.6 | Upgrade
|
Accounts Payable | 5.47 | 5.49 | 8.27 | 9.51 | 5.05 | 6.41 | Upgrade
|
Accrued Expenses | 16.95 | 44.1 | 34.56 | 31.3 | 20.19 | 24.05 | Upgrade
|
Current Portion of Leases | 13.16 | 14.65 | 12.16 | 11.08 | 10.31 | 6.81 | Upgrade
|
Current Unearned Revenue | 7 | 11.22 | 8.22 | 8.22 | 11.33 | 20.94 | Upgrade
|
Other Current Liabilities | 30.54 | 1.76 | - | - | - | - | Upgrade
|
Total Current Liabilities | 73.11 | 77.23 | 63.22 | 60.11 | 46.88 | 58.21 | Upgrade
|
Long-Term Leases | 17.97 | 20.38 | 24.37 | 32.86 | 16.07 | 19.32 | Upgrade
|
Long-Term Unearned Revenue | 103.78 | 106.64 | 60.67 | 60.67 | 60.89 | 73.98 | Upgrade
|
Other Long-Term Liabilities | 6.36 | 3.07 | 1.8 | - | - | 27.5 | Upgrade
|
Total Liabilities | 201.23 | 207.32 | 150.06 | 153.64 | 123.84 | 179.02 | Upgrade
|
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
Additional Paid-In Capital | 1,607 | 1,602 | 1,580 | 1,442 | 1,412 | 1,059 | Upgrade
|
Retained Earnings | -1,545 | -1,468 | -1,231 | -1,078 | -857.7 | -665.2 | Upgrade
|
Comprehensive Income & Other | 0.09 | 0.27 | 0.2 | -3.6 | -0.49 | -0.05 | Upgrade
|
Total Common Equity | 62.42 | 134.27 | 349.1 | 360.68 | 553.64 | 393.59 | Upgrade
|
Shareholders' Equity | 62.42 | 134.27 | 349.1 | 360.68 | 553.64 | 393.59 | Upgrade
|
Total Liabilities & Equity | 263.65 | 341.59 | 499.15 | 514.32 | 677.48 | 572.6 | Upgrade
|
Total Debt | 31.13 | 35.03 | 36.54 | 43.95 | 26.38 | 26.14 | Upgrade
|
Net Cash (Debt) | 189.83 | 234.88 | 390.6 | 393.43 | 593.54 | 485.64 | Upgrade
|
Net Cash Growth | -44.60% | -39.87% | -0.72% | -33.72% | 22.22% | 13.45% | Upgrade
|
Net Cash Per Share | 2.30 | 2.85 | 5.14 | 5.73 | 8.78 | 8.29 | Upgrade
|
Filing Date Shares Outstanding | 83.71 | 82.98 | 81.81 | 67.47 | 68.46 | 67.24 | Upgrade
|
Total Common Shares Outstanding | 83.71 | 82.73 | 81.77 | 67.35 | 68.44 | 62.56 | Upgrade
|
Working Capital | 151.73 | 212.09 | 277.61 | 296.64 | 460.43 | 360.88 | Upgrade
|
Book Value Per Share | 0.75 | 1.62 | 4.27 | 5.36 | 8.09 | 6.29 | Upgrade
|
Tangible Book Value | 62.42 | 134.27 | 349.1 | 360.68 | 553.64 | 393.59 | Upgrade
|
Tangible Book Value Per Share | 0.75 | 1.62 | 4.27 | 5.36 | 8.09 | 6.29 | Upgrade
|
Machinery | 22.66 | 30.88 | 26.37 | 25.55 | 22.72 | 19.17 | Upgrade
|
Construction In Progress | 0.19 | 0.83 | 2.06 | 1.57 | 1.53 | 0.86 | Upgrade
|
Leasehold Improvements | 10.24 | 11.75 | 9.65 | 9.76 | 8.16 | 4.97 | Upgrade
|
Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.